MétaCan
Menu
← Back to cohort

Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level.

2015· article· en· W2343867010 on OpenAlexaff
Ranjana H. Advani, Ian W. Flinn, Jeff P. Sharman, Catherine Diefenbach, Kathryn S. Kolibaba, Oliver W. Press, Laurie H. Sehn, Andy I. Chen, Gilles Salles, Hervé Tilly, Bruce D. Cheson, Sarit Assouline, Martin Dreyling, Anton Hagenbeek, Pier Luigi Zinzani, Cheryl Jones, Yu‐Waye Chu, Jamie Hirata, Michael Wenger, Franck Morschhauser

Bibliographic record

VenueJournal of Clinical Oncology · 2015
Typearticle
Languageen
FieldMedicine
TopicLymphoma Diagnosis and Treatment
Canadian institutionsJewish General HospitalBC Cancer Agency
Fundersnot available
KeywordsMedicineRefractory (planetary science)Internal medicineToxicityGastroenterologyFollicular lymphomaSurgeryAnimal scienceLymphoma

Abstract

fetched live from OpenAlex

8503 Background: Based on early evidence of cumulative toxicity of PoV at a dose of 2.4 mg/kg (Morschhauser ASH 2014 NCT01691898), a dose of 1.8 mg/kg was explored. We report updated results of the dose comparison. Methods: Pts with RR FL received PoV at 2.4 mg/kg or 1.8 mg/kg with R at 375mg/m2 q21d until progression or unacceptable toxicity. 5 pts from PhI (Palanca-Wessels ASH 2013) treated at the 2.4 mg/kg dose were included. Data at completion of PoV treatment were compared with data after 8 cycles. Results: 25 pts received PoV+R at 2.4 mg/kg, and 20 at 1.8 mg/kg. Median follow up was 14 mos for 2.4 mg/kg and 8 mos for 1.8 mg/kg. Baseline characteristics were balanced, except for age (median 68 yrs 2.4 mg/kg, 62 yrs 1.8 mg/kg) and tumor volume (SPD 1824 mm2 2.4 mg/kg, 2655 mm21.8 mg/kg). 40% (10/25, 2.4 mg/kg) and 50% (10/20, 1.8 mg/kg) of pts were refractory to their last treatment. Pts received a median of 10 cycles of PoV+R at 2.4 mg/kg vs. 9.5 at 1.8 mg/kg. Dose intensity through cycle 8 was 88% for 2.4 mg/kg and 99% for 1.8 mg/kg. Safety is shown in Table. An 84 yr old pt in the 2.4 mg/kg cohort died 2 months after cycle 12 due to pulmonary congestion. ORR was similar for both dose levels: 19/25 (76%) at 2.4 mg/kg, 15/20 (75%) at 1.8 mg/kg. CR: 11/25 (44%) at 2.4 mg/kg, 2/20 (10%) at 1.8 mg/kg. After 8 cycles, CR: 32% at 2.4 mg/kg and 10% at 1.8 mg/kg. Median PFS: 15 mo at 2.4 mg/kg, n.r. at 1.8 mg/kg. Conclusions: PoV+R in RR FL showed high ORR at both doses, with higher CR at 2.4 mg/kg. AEs and d/c rates were reduced at both doses if only the first 8 cycles are considered vs. those reported through study completion. The safety of PoV can be improved by shorter treatment and/or lower dose. Updated PFS will be presented. Clinical trial information: NCT01691898.Safety of PoV+R. PoV+R 1.8 mg/kg all cycles 2.4 mg/kg all cycles 1.8 mg/kg 8 cycles 2.4 mg/kg 8 cycles n (%) 20 25 20 25 Any AE G3-4 Neutropenia Febr neutropenia SAE Deaths AE leading to d/c G2-4 PN1 G3+ infection 10 (50) 7 (35) 2 (10) 6 (30) - 6 (30) 8 (40) 1 (5) 13 (52) 4 (16) 1 (4) 8 (32) 1 (4) 14 (56) 18 (72) 3(12) 10 (50) 7 (35) 2 (10) 6 (30) - 5 (25) 5 (25) 1 (5) 13 (52) 4 (16) 1 (4) 6 (24) - 7 (28) 10 (40) 2 (8) AE per CTCAE V4.03. AEs G3/4 ≥ 10% reported. 1MedDRA SMQ peripheral neuropathy.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.008

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.083
GPT teacher head0.407
Teacher spread0.324 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations19
Published2015
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicLymphoma Diagnosis and Treatment→French-language works237,207→